Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain

• Status: Active, not recruiting
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

In the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. In usual practice, some units are using qutenza in order to reduce neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut de Cancérologie de la Loire
• Treatments: Capsaicin

Criteria

Inclusion Criteria:

• Patient with at least 18 years old;

• Patient presenting neuropathic pain secondary to an anti-cancerous treatment;

• Patient presenting a DN4 (Neuropathic Pain in Four Questions) score superior or equal to 4 out of 10

• Patient presenting a skin without lesion at the painful area

• Informed consent form signed;

• Patient affiliated to a social security scheme.

Exclusion Criteria:

• Hypersensitivity known to capsaicin;

• Instable or uncontrolled hypertension;

• Painful area localised next to eyes;

• Pregnant or breastfeeding woman;

• Protected people.